Page last updated: 2024-11-04

cystathionine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Cystathionine: Sulfur-containing amino acid formed as an intermediate in the conversion of METHIONINE to CYSTEINE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cystathionine : A modified amino acid generated by enzymic means from homocysteine and serine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10104953
CHEBI ID165853
SCHEMBL ID81861
MeSH IDM0005532

Synonyms (15)

Synonym
cystathionine
(2s)-2-amino-4-(2-amino-2-carboxyethyl)sulanylbutanoic acid
allocystathionine
CHEBI:165853
AKOS015910039
SCHEMBL81861
(2s)-2-amino-4-[(2-amino-2-carboxyethyl)sulfanyl]butanoic acid
alpha-amino-gamma-(2-amino-2-carboxyethylmercapto)-butyric acid
dl-s-(2-amino-2-carboxyethyl)-homocysteine
a-amino-g-(2-amino-2-carboxyethylmercapto)-butyric acid
(2s)-2-amino-4-((2-amino-2-carboxyethyl)thio)butanoic acid
(2s)-2-amino-4-(2-amino-2-carboxyethyl)sulfanylbutanoic acid
d,l-cystathionine, 90per cent
AS-81710
(2s)-2-amino-4-((2-amino-2-carboxyethyl)thio)butanoicacid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Cadmium is a toxic metal and no effective antidote exists at present."( Modulation of cadmium chloride toxicity by sulphur amino acids in hepatoma cells.
Fotakis, G; Timbrell, JA, 2006
)
0.33
"Although many animal studies have reported that dietary excess of methionine causes toxic changes including growth suppression and hemolytic anemia, the biochemical mechanism and biomarkers for methionine toxicity have not been well elucidated."( Screening of toxicity biomarkers for methionine excess in rats.
Amao, M; Kawamata, Y; Kimura, T; Kodama, R; Sakai, R; Toue, S, 2006
)
0.33
" Nutritional and metabolic studies have employed amounts of methionine, including the d and dl isomers, both below and above the requirement and have not reported adverse effects in adults and children."( Toxicity of methionine in humans.
Garlick, PJ, 2006
)
0.33

Bioavailability

ExcerptReferenceRelevance
" Bioavailability studies with rats indicated that selenium in ramps was 15-28% more available for regeneration of glutathione peroxidase activity than inorganic selenium as selenite."( Tumorigenesis, metabolism, speciation, bioavailability, and tissue deposition of selenium in selenium-enriched ramps (Allium tricoccum).
Ip, C; Polan, CE; Uden, PC; Welbaum, G; Whanger, PD, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
"Chronic dosing of rats with isoniazid (INH) leads to an increase in the incidence of short "spontaneous" sprouts on motor end plates in the rat sternocostalis muscle."( The effects of chronic isoniazid intoxication on motor end plate sprouting in rat sternocostalis muscle and on responses to partial denervation and local botulinum toxin.
Cavanagh, JB; Kemplay, S, 1984
)
0.27
"2% completed their planned dosage within a 9-week feasibility time frame."( Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation.
Björkqvist, HG; Carlsson, GU; Gustavsson, BG; Kurlberg, GK; Odin, EA; Stoffregen, CC; Tångefjord, MT, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cysteine derivativeAn amino acid derivative resulting from reaction of cysteine at the amino group, carboxy group, or thiol group, or from the replacement of any hydrogen of cysteine by a heteroatom. The definition normally excludes peptides containing cysteine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (568)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990290 (51.06)18.7374
1990's69 (12.15)18.2507
2000's89 (15.67)29.6817
2010's85 (14.96)24.3611
2020's35 (6.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials23 (3.89%)5.53%
Reviews29 (4.91%)6.00%
Case Studies20 (3.38%)4.05%
Observational1 (0.17%)0.25%
Other518 (87.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]